Strides Shasun plans to file 15-20 product applications in the US in FY18 - ( via NewsPoints Desk)

  • Strides Shasun executive director Badree Komandur said the company plans to step up product filings with the FDA starting in the current financial year, reported

  • "Regulated markets like the US and Australia will be the real focus of the company," Komandur said, adding that "our R&D pipeline and product commercialization will drive growth."

  • Specifically, the company plans to file 15 to 20 abbreviated new drug applications (ANDAs) with the FDA annually, as against 10 to 12 applications earlier, he said.

  • "Once we start getting more approvals, and that is expected because all our plants have been inspected and got clearance, the momentum in the US will pick up," Komandar said.

  • Separately, Strides said it signed definitive agreements with Vivimed Labs for two joint venture (JV) companies, one each in India and Singapore.

  • The Indian JV will own an FDA-approved formulations facility in Chennai, and the Singapore JV will own certain approved ANDAs and product pipeline. This transaction is expected to close by the end of this month, the news source said. 

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.